GSK acquires 35Pharma

GSK agreed to acquire 35Pharma. Reported deal value: $950M. Status: Announced. Sector: biopharmaceutical. Target headquarters context: Location not specified.

This page summarizes publicly available information about the transaction as of 2026-02-25. Figures and status may change as filings and press coverage update.

Advanced Search GSK to acquire 35Pharma for $ 950m including a potential drug for pulmonary hypertension PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide In a deal worth $ 950m , GSK has agreed to acquire 35Pharma , a private, clinical-stage biopharmaceutical company based in Canada that specialises in the development of novel protein-based therapeutics